Skip to content

Validation Study of a New Digital Treatment Test

Validation Study of a New Digital Treatment Test Based on Interactive Video Games for Alzheimer's Disease

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04897464
Enrollment
60
Registered
2021-05-21
Start date
2021-06-01
Completion date
2022-05-31
Last updated
2021-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer Disease, MCI

Brief summary

Oculomotor behavior and cognitive processing of visual information are intimately connected. AD patients show ocular movement problems. Oculomotor deficits are broad consisting mainly of different saccade metrics, altered pupil responses. and smaller and irregular eye vergence movements. Here we test an interactive eye-tracking game to improve eye motion control and thereby training cognitive behavior

Interventions

OTHERBGaze therapy Alzheimer

BGaze Therapy is an interactive eye tracking game

Sponsors

Braingaze
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
50 Years to 85 Years
Healthy volunteers
Yes

Inclusion criteria

1\) Clinical diagnosis of MCI or AD

Exclusion criteria

1. Severe cognitive deterioration 2. History of neurological disease with clinically relevant impact on cognition 3. Severe psychiatric disorder 4. Incidental structural brain findings with impact on cognitive impairment 5. Presence of relevant visual problems

Design outcomes

Primary

MeasureTime frameDescription
MoCAimmediately after the interventionMeasure changes in MoCA
MMSEimmediately after the interventionMeasure changes in MMSE

Secondary

MeasureTime frameDescription
CANTABimmediately after the interventionMeasure changes in CANTAB tests

Countries

Spain

Contacts

Primary ContactHans Super
hans@braingaze.eu0034931696572
Backup ContactLaszlo Bax
Laszlo@braingaze.eu0034931696572

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026